1.. INTRODUCTION
================

Proteoglycans are an integral part of the extracellular matrix of all tissues \[[@R1]\]. In some tissues proteoglycans are a low component by mass but are highly important because they are both structural molecules and actively involved in critical cell functions including proliferation, migration, phenotypic expression and secretion \[[@R2]\]. Proteoglycans are complex macromolecules comprised of a core protein and one or more covalently attached glycosaminoglycans (GAG) chains so that structurally they are both proteins and carbohydrates. The spectrum of properties of proteoglycans is determined by both the core proteins and the GAG chains. Core proteins determine the cellular location and serve as scaffolds for the GAG chains and the highly ionic chains determine physical properties of tissues and bind factors including growth factors and apolipoproteins. The complementary roles of core protein and GAG are exemplified by the observation that binding of Low Density Lipoproteins (LDL) to GAG chains of intact proteoglycans occurs with an order of magnitude higher affinity than the binding to free GAG chains \[[@R3]\]. There is considerable interest in the biosynthetic pathways determining proteoglycan and particularly GAG structure because GAG chains are implicated in many fundamental biological and pathological processes \[[@R4]\]. The signaling pathways regulating core protein synthesis and GAG elongation are of specific interest. The pathways regulating these two processes are distinct with initial evidence indicating that the signaling pathway regulating core protein expression is aligned to that of the cell cycle whereas the signaling pathway regulating elongation of GAGs has some distinct properties \[[@R5]\]. The biochemical mechanisms and signaling pathways regulating the synthesis of GAG chains are the focus of this review.

The GAG chains consisting of a tetrasaccharide linkage region and repeating disaccharide moieties are sulfated galactosaminoglycans in the case of chondroitin sulfate (CS) and dermatan sulfate (DS) proteoglycans. CS and DS GAGs are initially synthesized as CS GAGs (containing glucuronic acid (GlcA)) and the activity of the enzyme C5--epimerase to isomerize GlcA to Iduronic acid (IdoA) by definition generates DS GAGs \[[@R6]\]. Thus this review refers to CS GAG synthesis but the discussion, allowing for the action of C5 -- epimerase, also relates to DS GAG chains. The major CS proteoglycans are aggrecan, which forms a substantial structural component of cartilage and is composed of both CS and keratan sulfate GAG chains, and the large CS proteoglycan versican which is prominent in blood vessels. The smaller leucine--rich proteoglycans, biglycan and decorin, are CS GAG with some epimerase modification rendering them DS proteoglycans and they are also prominently expressed in blood vessels \[[@R7]\]. The highly ionized state of the sulfated GAG chains leads to their role in determining the physical properties of tissues such as the resistance to compression of cartilage provided by aggrecan. The loss of CS from cartilage is a major cause of osteoarthritis \[[@R8]\]. Conversely, the accumulation of biglycan in the wall of injured blood vessels leads to the trapping of apolipoproteins and is recognized as the initiating factor in atherosclerosis which underlies most cardiovascular disease \[[@R9],[@R10]\].

Although GAGs have critical biological roles the precise mechanism by which CS GAG polymers are synthesized is unknown. Until recently, no *in vitro* system has proven capable of synthesizing GAG chains of similar length to those secreted by cells and occurring in tissues. GAG chains do not have a discrete molecular weight but rather have a spectrum of values which can be readily observed by SDS--PAGE (see Fig. (**[1](#F1){ref-type="fig"}**) Lower Panel) or size exclusion analysis plots \[[@R11]\]. The range of normal GAG chain lengths is very wide and extends from 20 to approximately 60 KDa corresponding to approximately 40-120 disaccharides. Proteoglycans, such as biglycan, have endogenous synthesis and superimposed upon it the phenomena of GAG hyperelongation. In this response, agonists, such as hormones and growth factors stimulate signaling pathways leading to elongation and thus an increase in the average molecular weight \[[@R12],[@R13]\] (see Fig. **[1](#F1){ref-type="fig"}**). Growth factor signaling pathways can also alter epimerization and the disaccharide sulfation pattern and all these structural alterations are considered to have functional consequences \[[@R14]\].

This article addresses the question of whether the hyperelongation effect is an extension of or is distinct from the basic GAG chain polymerizing process. To relate structure to function we use the example of the binding of CS/DS GAG chains to apolipoproteins on lipids and the GAG structural features affecting this interaction \[[@R15]\]. We further consider if it may be possible to dissect the basic mechanisms of GAG synthesis associated with the physiological roles of these molecules, from the mechanisms of hyperelongation that represent a target for the prevention of lipid retention diseases such as atherosclerosis and calcific aortic valve disease (CAVD) \[[@R14],[@R16],[@R17]\].

2.. BIOCHEMISTRY OF GAG SYNTHESIS
=================================

CS/DS GAGs on proteoglycans are synthesized by the initial addition of a xylose (Xyl) residue to a specific serine in the core protein followed by the sequential addition of two galactose (Gal) and one GlcA residues to form the tetrasaccharide linkage region (GlcAβ1-3Galβ1-3Galβ1-4Xylβ1-O-Ser) \[[@R18]\] (see Fig. **[1](#F1){ref-type="fig"}**). The Xyl and Gal residues in this region can be modified by phosphorylation and sulfation and these modifications have a profound influence on subsequent GAG chain synthesis \[[@R19]\]. Transfer of a βGalNAc residue to the terminal GlcA of the linkage region initiates chain polymerization and thus the sequential alternate transfer of GalNAc and GlcA forms the disaccharide repeat units of the polymerizing GAG chain. The GAG chain is subject to sulfation and epimerization to yield further structural heterogeneity \[[@R18]\]. Whereas the core protein has a defined molecular weight derived from its mRNA coding and amino acid structure, the GAG chains have a range of sizes conferring a range of molecular weights to the whole proteoglycan. Approximately 15 enzymes have been cloned which undertake these steps of linkage region and CS GAG synthesis but the manner in which they affect GAG polymerization is unknown \[[@R18]\].

A further important consideration of GAG chain structure in tissues is that numerous factors can stimulate cells to produce modified, particularly elongated GAG chains, which we term hyperelongated GAGs \[[@R10],[@R16]\]. Although the outcome of cell stimulation leading to modification of CS GAGs is clearly established, only in the last decade have the signaling pathways begun to be defined and nothing is known of the link between the signaling pathways and the precise biochemical modifications that lead to the changes in GAG structure.

3.. ENZYMES REGULATING THE SYNTHESIS OF CS GAG CHAINS
=====================================================

GAG chain initiation and attachment to the core protein occurs principally within the linked compartments of the endoplasmic reticulum (ER) and the *cis* and *trans* Golgi. CS, DS and heparan sulfate (HS) GAG chains are attached to serine residues of core proteins *via*an O-linked glycosidic bond. A single consensus sequence for GAG chain initiation has not been defined although serine residues flanked by glycine appear to be involved \[[@R18]\]. A tetra-saccharide linkage region is initiated by the action of the enzyme UDP--Xyl transferase to attach the pentose sugar, Xyl, to a serine residue on the core protein \[[@R20]\]. Addition of the linker region occurs in a compartment intermediate to the endoplasmic reticulum and the Golgi apparatus \[[@R1]\]. Construction of the tetrasaccharide linkage region continues with the addition of two galactose (Gal) units by UDP-Gal transferase I and II respectively and is completed upon addition of GlcA by UDP-GlcA transferase I \[[@R21]\]. The addition of characteristic repeating disaccharide units differs at this point which is a divergence point for the biosynthesis of different types of GAG chains. Intriguingly, modifications including sulfation and phosphorylation of the tetrasaccharide linkage region may influence the resultant GAG types \[[@R19],[@R22],[@R23]\].

Multiple enzymes involved in the sequential addition of monosaccharides, have been identified, cloned and their transferase and polymerase activities characterized \[[@R24]-[@R29]\]. GalNAc transferase I and II and GlcA transferase II are involved in CS biosynthesis and the enzyme C-5 GlcA epimerase converts CS to DS. For comparison, for heparin and HS synthesis the enzymes EXTL2, EXT1, EXT2, several NDSTs and C-5 GlcA epimerase have been identified \[[@R21]\]. Sulfation of the GAG chains also occurs in the Golgi apparatus, where sulfotransferases add sulfate groups from 3'phosphoadenosine-5'phosphosulfate (PAPS) to specific positions on the emerging polysaccharide chain \[[@R30]\].

4.. TRANSFERASES POLYMERASES AND THE DETERMINATION OF "NATURAL" GAG LENGTH
==========================================================================

The "natural" length of GAG chains is defined as the length of GAG chain synthesized by the GAG elongation machinery operating in a cell which is not stimulated by external stimuli which cause additional elongation of GAG chain length \[[@R16]\] (see Fig. (**[1](#F1){ref-type="fig"}**) for schematic representation). Presently six homologous enzymes have been cloned which can undertake the addition of a monosaccharide to an acceptor oligosaccharide and thus have the potential to undertake CS GAG polymerization. The designations of the enzymes involved in GAG polymerization have been evolving over the last decade so it is noted that the text of this manuscript utilizes the designations as used in the quoted references and these can be checked against the designations compiled in Table **[1](#T1){ref-type="table"}**. Notably, although these enzymes act as monosaccharide transferases, when expressed individually they do not manifest polymerase activity sufficient to generate GAG chains similar to those produced by intact cells. Recent advances described below, have revealed that the enzymes need to be expressed in combinations to achieve polymerization activity. The genes for these enzymes are localized on different chromosomes despite significant homology in the nucleotide and amino acid sequences \[[@R31]\].

None of the individual enzymes possesses polymerase activity *in vitro* sufficient to produce a run of disaccharide repeat units that would constitute a GAG chain. ChSy--1 and ChPF show similar tissue distributions whereas ChSy--2 and ChSy--3 each show a specific tissue distribution which is distinct from the first mentioned pair of enzymes \[[@R32]\]. ChSy-1, 2 and 3 along with ChPF have all been shown to colocalise in the Golgi where they work in an orchestrated manner to manifest GAG polymerization \[[@R33]\]. It has emerged that some of these enzymes exhibit transferase and polymerase activity whereas some act as chaperones which bind to partners to generate complexes which show polymerization activity. Importantly, polymerization activity of the different combinations of glycosyltransferases and chaperones is variable and so is the length of the resultant GAG chains which are synthesized by various different combinations of enzymes \[[@R32]\].

The chondroitin glycosyltransferases, ChGn--1 and ChGn--2 (GalNAcT--1 and --2), are apparently not essential for CS GAG polymerization and notably homologues of these transferases are not present in*Caenorhabditis elegans*which does possess chondroitin GAGs \[[@R34]\]. It is unclear why so many CS synthesizing enzymes exist in nature. It is notable that no cell lines with greatly disrupted CS biosynthesis have been reported and this may be due to a high level of functional redundancy that is conferred by having a family of polymerization enzymes available. The existence of multiple polymerizing enzymes, which when expressed in different relative abundances synthesize GAG chains of different lengths provides an explanation for the existence of variability in the length of GAG chains occurring in different tissues, at different developmental stages and in disease states \[[@R8],[@R35],[@R36]\]. Differential expression associated with varying GAG polymerizing activity also provides a possible mechanism for the action of external stimuli to modify GAG length which could occur, for example, by alterations in the relative expression of the enzymes and chaperones. The implications for different GAG lengths in different tissues and in different physiological and pathological states is presently unknown.

Most glycosyltransferases contain a DXD motif which is critical for catalytic function possibly by modulation of the binding of UDP--sugars through the coordination of a divalent cation \[[@R37],[@R38]\]. ChPF lacks the usual DXD motif characteristic of Golgi resident enzymes which opens the possibility of a different role from the integral membrane enzymes including the possibility that it may be rate limiting and amenable to altered expression which can alter the length of GAG chains \[[@R29]\].

Kitagawa and colleagues \[[@R32]\] showed that ChPF when expressed alone does not show polymerization activity but when it is expressed with other enzymes it is capable of mediating chain polymerization. Furthermore, the size of the GAG chains is dependent upon the glycosyltransferase partner. For example, when ChPF is co-expressed and partners with ChSy-1 the resultant GAG chains are longer than when it is coexpresssed with ChSy-2 \[[@R32]\].

Each of ChSy-1,2 and 3 contain one domain with glycosyltransferase activity and accordingly pairs of enzymes carry two functional domains. Kitagawa and colleagues also examined the effect of mutating out the glycosyltransferase activity of ChSy--3 whilst demonstrating that the resultant protein did interact with other glycosyltransferases \[[@R33]\]. When evaluated for polymerization activity it was found that in the ChSy--3:ChSy--1 complex both domains contributed equally to polymerization however for the ChSy2:ChSy--3 complex the ChSy--3 contributed totally to the polymerization activity and the ChSy--2 served only, but critically, as a chaperone \[[@R33]\].

CS polymerization complexes also bind to the proteoglycan core protein or an equivalent initiation protein and the nature of the core protein can determine the extent of GAG polymerization observed. Furthermore, CS GAG synthesis is initiated on xyloside derivatives \[[@R3],[@R39]\] and the nature of the hydrophobic aglycone of the xyloside derivative can determine both the type of GAG chain as well as the length of the resultant chains. Thus, the polymerizing activity of the various transferase complexes is modulated by the interaction with the recognition sequence of the proteoglycan core protein or artificially by the nature of the hydrophobic aglycone of a xyloside derivative.

Enzymatic sulfation during synthesis of the GAG chain is suggested to play a role in determining ultimate GAG length. Sulfation proceeds with polymerization and specific sulfate groups have stimulatory or inhibitory effects on GalNAc and GlcA transfer \[[@R24],[@R40]\]. Early studies suggested that 4,6-O sulfation on GalNAc and 3--O-sulfation on GlcA residues at the non-reducing end might be involved in terminating polymerization of CS GAG chains \[[@R41]\]. A deeper understanding of the processes of CS GAG polymerization will almost certainly provide insights into the molecular mechanisms through which supplementary chain modifications such as sulfation modulate GAG length and may therefore reveal tissue specific effects which will inform considerations of function.

Protein:protein interactions are pH sensitive and the pH alters throughout the Golgi apparatus. The pH generally decreases along the secretory pathway within the Golgi with a variation of as much as 0.5 pH units \[[@R33]\]. Coexpression of pairs of ChSy--3, ChSy --1 and ChPF using GlcUAβ1--3GalβO -- NM as an acceptor generates GAGs of differing length and the length is dependent upon the pH of the assay \[[@R33]\]. Thus, the localization of the glycosyltransferases in the Golgi and the pH at the relevant position becomes another determinant of natural GAG length.

Thus, full polymerization activity requires a complex of at least two of the four critical polymerization enzymes (ChSy--1, --2, --3 and ChPF) and the resultant polymerization capacity is variable depending upon the entities that form the complexes and the core protein to which they direct their activity. In summary, it is possible to speculate that the factors that determine natural GAG length in tissues are the specific and relative level of expression of the six or perhaps only four enzymes shown in Table **[1](#T1){ref-type="table"}** (i.e. requirement for transferase *versus* polymerase activity), the respective core protein, the pH of the Golgi subcompartments and the sulfation of the disaccharides in the forming GAG chain.

5.. MECHANISMS LEADING TO THE HYPERELONGATION OF CS GAG CHAINS
==============================================================

Cells synthesize CS proteoglycans with GAG chains of "natural" length due to the basal activity of the enzymes, transporters and processes associated with GAG biosynthesis in the cell, as described above. However, treatment of cells such as vascular smooth muscle cells (VSMC) with growth factors such as platelet--derived growth factor (PDGF), transforming growth factor (TGF)β, angiotensin II and metabolic agents including oxLDL leads to the synthesis and secretion of CS/DS proteoglycans which are larger than those from untreated cells \[[@R3],[@R12],[@R42],[@R43]\]. For a specific example of the effect of treating cells with TGFβ on the size of the resultant proteoglycans see Fig. (**[1](#F1){ref-type="fig"}**) (lower panel). Size increases of proteoglycans are due to elongation of the GAG chains which can be demonstrated by the chemical cleavage of the chains from the core proteins and GAG size analysis by SDS--PAGE, size exclusion chromatography or fluorophore assisted carbohydrate electrophoresis (FACE) \[[@R3],[@R44]\]. The increase in size of the GAG chains is approximately 10-20 per cent \[[@R3]\]. Some growth factors such as PDGF also cause an increase in the 6-sulfation of the CS/DS GAG chain but others such as TGFβ only cause GAG elongation \[[@R45]\]. CS GAG chains may also be modified by epimerization which changes the sugars from GlcA to IdoA (and hence CS to DS GAG chains). Although this has the potential to modify the interaction with apolipoproteins little is known of the role of growth factors and other stimuli in regulating this reaction \[[@R18]\]. We have observed that GAGs secreted by cultured VSMCs have a particularly high CS versus DS content suggesting that epimerase activity may be down regulated in such cultured cells (Little and Nigro, unpublished observation).

The signaling pathways downstream of receptor activation mediating GAG hyperelongation are complex and in some cases novel pathways appear to be involved. Using the example of VSMCs several growth factors including PDGF, TGFβ and thrombin have been shown to mediate GAG (hyper)elongation and the signaling pathways eliciting this response have been partially characterized. Schonherr *et al*. \[[@R5]\] reported that PDGF stimulates GAG elongation of CS GAGs by monkey VSMCs however the response is not blocked by the isoflavone, genistein. Genistein, the prototypical inhibitor of the intrinsic tyrosine kinase autotransphosphorylation activity of the dimeric PDGF receptor and is an inhibitor of PDGF--mediated mitogenic signaling in VSMC \[[@R5]\]. The data of Schonherr *et al*. \[[@R5]\] leads to the implication that there may be a PDGFR tyrosine kinase independent signal transduction pathway controlling GAG elongation. There is evidence for this in that PDGF--stimulated early growth response gene (egr)--1 expression in 3T3 fibroblasts cells is also not blocked by genistein \[[@R46]\].

The action of TGFβ to stimulate CS/DS GAG elongation in human VSMCs involves the canonical Smad/phospho-Smad 2/3 pathway but also has the novel aspect that it engages the p38/phospho p38 Mitogen Activated Protein Kinase (MAPK) pathway usually associated with stress signaling \[[@R13]\].

The action of the serine protease, thrombin to stimulate GAG elongation in VSMCs is mediated *via*the Protease Activated Receptor--1 and involves protein kinase C and transactivation of the Epidermal Growth Factor receptor \[[@R47]\].

The precise biochemical mechanism(s) through which the signaling pathways activated by growth factors lead to hyperelongation of GAGs is unknown. ALK V/Smad and p38 MAPK signaling pathways generate signaling intermediates which move to the nucleus and act as transcription factors. These transcription factors may for example alter the expression of the GAG polymerizing enzymes however studies of the regulation of GAG polymerizing enzymes have so far not yielded substantial advances \[[@R13],[@R48]\]. ChPF has recently been discovered and shown to play a role in CS GAG polymerization *in vitro* \[[@R32]\]. Whether or not the growth factors may be regulating the expression and action of ChPF is an interesting question. ChSy--1 leads to longer GAG chains *in vitro* than ChSy--2 (when each is co expressed with ChPF) so one possibility is that hyperelongation may occur due to a shift in the major enzyme from ChSy--2 to ChSy--1. For example, both enzymes may be involved in the synthesis of natural length GAG chains -- leading to the spectrum of chain sizes observed -- and growth factors may stimulate the expression of ChPF which is targeted within the cell at ChSy--1 thus yielding longer GAG chains.

6.. DIFFERENTIATING NATURAL GAG SYNTHESIS FROM GAG HYPERELONGATION
==================================================================

GAG formation is performed by a number of membrane bound enzymes located in the Golgi apparatus \[[@R18]\]. As discussed, a variety of agonists can stimulate elongation of GAG chains \[[@R3],[@R12],[@R42],[@R43]\]. The signaling pathways through which agonists mediate GAG elongation are being revealed and represent known and possibly novel pathways. It is unknown how these signaling pathways mediate their effects to cause GAG elongation. An interesting question is whether or not natural GAG synthesis and agonist-mediated hyperelongation involves the synthesis of new proteins? Vijayagopol and colleagues \[[@R49]\] showed that a growth factor mixture (conditioned media) derived from endothelial cells and containing TGFβ stimulated an increase in the size of proteoglycans and thus by implication the size of the GAG chains produced by bovine aortic smooth muscle cells. The GAG elongation was blocked by cycloheximide which prevents *de novo* protein synthesis and also by the transcription inhibitor actinomycin D \[[@R49]\]. We have recently confirmed some of these results in human VSMCs where cycloheximide inhibits PDGF mediated GAG elongation (Ballinger and Little, unpublished observations). The data that cycloheximide inhibits growth factor mediated GAG elongation but not basal GAG synthesis, demonstrates that the synthesis of natural GAGs does not involve *de novo* protein synthesis (in the relatively short timeframe of the experiment) but the ability of growth factors to cause GAG hyperelongation is dependent upon *de novo* protein synthesis. There are several possible interpretations of these results. It is likely that the integral membrane enzymes mediating the synthesis of natural GAGs have a slow turnover rate due to the more stable environment within the membranes of the Golgi apparatus. The Golgi resident enzyme galactosyltransferase in which the mature enzyme is phosphorylated has an average half life of about 19 hours \[[@R50],[@R51]\]. Although it is obvious that there must be some turnover and thus new synthesis of enzymes required for GAG synthesis it is possible that the need to replenish these enzymes as they are naturally degraded is very slow. Although the synthesis of natural GAGs on proteoglycans does not require *de novo* protein synthesis the action of growth factors to hyperelongate GAGs is clearly dependent upon the synthesis of new protein. There are at least two possibilities for the role of this newly synthesized protein in mediating GAG elongation -- either the signaling pathway linking receptor activation and GAG hyperelongation involves gene expression and new protein synthesis or the agonist is causing the increased expression and synthesis of a factor or cofactor which is rate limiting in GAG synthesis \[[@R32]\]. For example, in the pathway that TGFβ stimulates biglycan expression in PANC-1 and MG-63 cells, the initial stimulation of Smad phosphorylation is followed by the expression and synthesis of GADD45β which activates p38 MAPK \[[@R52]\]. This is a rapid response and it would be expected that acute cycloheximide treatment could block this pathway.

Thus, there appears to be a clear difference between natural GAG synthesis and GAG hyperelongation and a schema is shown in Fig. (**[2](#F2){ref-type="fig"}**). The fact that GAG hyperelongation has very specific signaling pathways that involve *de novo* protein synthesis further validates GAG hyperelongation as a potential therapeutic target \[[@R14],[@R16],[@R17]\].

7.. CONCLUSIONS
===============

Recent advances in the cloning and expression of CS glycosyltransferases have identified six functional enzymes, four of which appear to be the most important for CS GAG polymerization. These proteins work in combination, certainly at least in pairs, to manifest CS GAG polymerization to form tissue specific "natural" CS GAG polymers. The relative level of expression of the respective enzymes, the specific proteoglycan core protein, pH of the Golgi subcompartments and the activity of sulfotransferases are factors that determine natural GAG length.

Superimposed on this basic cell biology of CS GAG synthesis are the external factors that have classic cell surface receptors and intracellular signaling pathways that can modify the ultimate GAG length most specifically leading to GAG elongation of the order of 20 percent. This GAG elongation is functionally significant because it leads to enhanced binding to LDL which is closely associated with the earliest stages of the initiation of atherosclerosis \[[@R9],[@R14]\]. How the signaling pathways link to GAG elongation and whether or not this is due to an impact on natural GAG synthesis or the superimposition of a distinct process is presently unknown. This is an important question because if GAG hyperelongation can be separated from natural GAG synthesis then it may lead to identification of a therapeutic target which allows for the prevention of disease without interfering with the physiological role of proteoglycans.
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![Schema and actual experimental depiction of the structure of "natural" and "hyperelongated" chondroitin and dermatan sulfate glycosaminoglycan (GAG) chains. Natural or basal GAG chains are defined in the text and the hyperelongation of GAG chains (as indicated in the figure -- Upper Panel) occurs, for example, when vascular smooth muscle cells are stimulated with growth factors such as TGFβ. The electrophoretic mobility of intact ^35^S-SO~4~ labeled proteoglycans can be assessed by SDS-PAGE (4-20 % acrylamide gradient gel) using a fixed amount of radioactivity per lane. The SDS-PAGE gel of the biglycan produced and secreted by vascular smooth muscle cells treated with various concentrations of TGFβ for 24 h is shown (Lower Panel) where the decreasing migration of the biglycan band with increasing TGFβ occurs due to the lengthening of the GAG chains (see text for references). In the context of the current paper, the band in lane 2 (second from left) is natural or basal biglycan and the bands in lanes 3 to 9 are hyperelongated biglycan derived from cells treated with TGFβ or PDGF (platelet-derived growth factor). See text and references therein for further details.](TOBIOCJ-2-135_F1){#F1}

![Schema of the biochemical processes leading to the synthesis of natural chondroitin sulfate glycosaminoglycan (GAG) chains and the hyperelongation of GAG chains elicited by multiple cell signaling pathways resulting from the action of growth factor such as PDGF and TGFβ. ChSy chondroitin synthase; ChPF chondroitin polymerizing factor. The scheme to the left shows the normal biosynthesis of a proteoglycan core protein which is new protein and therefore cycloheximide sensitive but is also subject, based on individual and specific core proteins, to up regulation by growth factors. Various combinations, at least pairs of polymerases (see Table **[1](#T1){ref-type="table"}**) add monosaccharides to the preformed tetrasaccharide linkage region on a serine residue on the core protein to produce the "natural" length glycosaminoglycan (GAG) chain. To the right of the scheme it is indicated that growth factors can intervene to result in the production of longer, so called hyperelon-gated GAG chains and although this is cycloheximide sensitive (see text) and acutely requires new protein synthesis the site at which the new protein synthesis occurs, either in the signaling pathway or in the actual transporters and enzymes that synthesis GAGs is unknown. The GAG elongation in response to growth factors is of the order of 20 per cent but this is sufficient to half the affinity of binding of the GAG chain to LDL.](TOBIOCJ-2-135_F2){#F2}

###### 

Designation of the six human enzymes associated with chondroitin sulfate glycosaminoglycan chain polymerization. Note that an additional eight or more enzymes can be involved in the synthesis of GAG chains, some of which may impact of GAG elongation, but this table and paper focuses on those enzymes primarily involved in GAG chain polymerization

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Transferase/Polymerase                      Name[1](#T1FN1){ref-type="table-fn"}   EC Number[2](#T1FN2){ref-type="table-fn"}   Gene Name    References
  ------------------------------------------- -------------------------------------- ------------------------------------------- ------------ --------------------
  Chondroitin sulfate\                        CGAT1                                  2.4.1.174                                   CSGALNACT1   \[[@R26], [@R27]\]
  N-acetylgalactosaminyltransferase 1                                                                                                         

  Chondroitin sulfate\                        CGAT2                                  2.4.1.174                                   CSGALNACT2   \[[@R53], [@R28]\]
  N-acetylgalactosaminyltransferase 2                                                                                                         

  Chondroitin sulfate glucuronyltransferase   CHGUT                                  2.4.1.226                                   CSGLCAT      \[[@R26]\]

  Chondroitin sulfate synthase 1              CHSS1                                  2.4.1.226\                                  CHSY1        \[[@R24], [@R29]\]
                                                                                     2.4.1.175                                                

  Chondroitin sulfate synthase 2              CHSS2                                  2.4.1.226\                                  CHPF         \[[@R29]\]
                                                                                     2.4.1.175                                                

  Chondroitin sulfate synthase 3              CHSS3                                  2.4.1.226\                                  CHSY3        \[[@R31]\]
                                                                                     2.4.1.175                                                
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

Nomenclature of the UniProt Knowledgebase of ExPASy Proteomics server.

Transferase activities are: EC 2.4.1.174, EC 2.4.1.175 is N-acetylgalactosaminyltransferase (GalNAc transferase) activity; EC 2.4.1.226 is Glucuronyltransferase (GlcA transferase) activity.
